Marchex - MCHX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marchex in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MCHX shares.
View MCHX analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued twelve-month price objectives for Marchex's stock. Their MCHX share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts price targets for MCHX or view top-rated stocks among Wall Street analysts.

Marchex's stock was trading at $2.48 at the beginning of the year. Since then, MCHX shares have decreased by 31.5% and is now trading at $1.70.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our MCHX earnings forecast.

Marchex, Inc. (NASDAQ:MCHX) issued its earnings results on Tuesday, November, 9th. The technology company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.04. The technology company had revenue of $13.70 million for the quarter, compared to analyst estimates of $14.37 million. Marchex had a negative trailing twelve-month return on equity of 6.79% and a negative net margin of 12.73%. During the same period in the prior year, the business posted ($0.05) earnings per share.

8 employees have rated Marchex Chief Executive Officer Russell Horowitz, Michael Arends, and Ethan Caldwell. on Glassdoor.com. Russell Horowitz, Michael Arends, and Ethan Caldwell. has an approval rating of 58% among the company's employees. This puts Russell Horowitz, Michael Arends, and Ethan Caldwell. in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marchex investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Enphase Energy (ENPH), NVIDIA (NVDA), OPKO Health (OPK), Nokia Oyj (NOK), Overstock.com (OSTK), Block (SQ) and Zynga (ZNGA).

Marchex trades on the NASDAQ under the ticker symbol "MCHX."

Marchex's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.50%), Heartland Advisors Inc. (0.60%) and Dimensional Fund Advisors LP (0.48%). Insiders that own company stock include Edenbrook Capital, Llc, John Roswech, Long Only Value Fund Edenbrook and Michael A Arends.
View institutional ownership trends.

Shares of MCHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MCHX stock can currently be purchased for approximately $1.70.

Marchex (NASDAQ:MCHX) has a market capitalization of $72.19 million and generates $53.48 million in revenue each year. The technology company earns $-4,390,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

The company employs 187 workers across the globe.

Marchex's mailing address is 520 PIKE STREET SUITE 2000, SEATTLE WA, 98101. The official website for the company is www.marchex.com. The technology company can be reached via phone at (206) 331-3300, via email at ir@marchex.com, or via fax at 206-331-3695.